Perry Ellis International (Nasdaq:PERY) announced that it has entered into license agreements with Parigi Group Ltd. for boy’s and girl’s casual sportswear, activewear and swim for sizes newborn to 20 in the U.S. and Canada under the Perry Ellis and Original Penguin trademarks. The company will continue to partner with LF U.S.A. Inc. for Perry Ellis Portfolio® boy’s dress wear. The new collections launch in better department stores, with Original Penguin available for spring 2015 and Perry Ellis for Back to School 2015. Perry Ellis International, Inc. (NASDAQ:PERY) shares after opening at $14.21 moved to $14.64 on last trade day and at the end of the day closed at $14.54. Company price to sales ratio in past twelve months was calculated as 0.24 and price to cash ratio as 4.61. Perry Ellis International, Inc. (NASDAQ:PERY) showed a positive weekly performance of 3.34%.
TheStreet Ratings team rates Chipotle Mexican Grill, Inc. (NYSE:CMG) as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:We rate CHIPOTLE MEXICAN GRILL INC (CMG) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. Chipotle Mexican Grill, Inc. (NYSE:CMG) shares fell -5.94% in last trading session and ended the day on $519.61. CMG return on equity ratio is recorded as 23.10% and its return on assets is 17.60%. Chipotle Mexican Grill, Inc. (NYSE:CMG) yearly performance is 58.24%.
Societe Generale reissued their buy rating on shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) in a research report released on Thursday morning,StockRatingsNetwork.com reports. Societe Generale currently has a GBX 1,981 ($33.14) price objective on the stock. GlaxoSmithKline plc (ADR) (NYSE:GSK) shares moved down -0.59% in last trading session and was closed at $52.51, while trading in range of $52.28-$52.75. GlaxoSmithKline plc (ADR) (NYSE:GSK) year to date performance is -0.32%.
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company, announced that WoundSource™ has highlighted NovaBay’s NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or ‘flesh-eating’ infections.NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) weekly performance is -1.87%. On last trading day company shares ended up $1.05. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) distance from 50-day simple moving average is -12.09%. Analysts mean target price for the company is $2.50.
Leave a Reply